GENE ONLINE|News &
Opinion
Blog

2022-04-21| Asia-Pacific

Asahi Kasei Medical Ups CDMO Business in the US with Bionova Buy

by Joy Lin
Share To

Asahi Kasei Medical, a Japanese medical device and pharmaceutical manufacturing company, is proceeding with plans to buy, through a US subsidiary, Bionova Scientific LLC, a US-based CDMO that caters especially to biopharmas developing antibody-based drugs.

Related Article: How CDMOs are Restructuring the Biopharma Landscape – An Interview with Bobby Sheng

Brief Profile of Asahi Kasei Medical

 

Asahi Kasei Medical is the healthcare segment of Asahi Kasei Group, a Japanese chemical company founded 90 years ago. Asahi Kasei Medical became one of the Group’s core operating companies in 2008; following the 2012 acquisition of US-based ZOLL Medical Corporation, the company expanded into acute critical care. Since then, the company has been focusing on expanding its bioprocess business. 

Besides selling Planova virus removal filters and bioprocess equipment, Asahi Kasei Medical has reached into the field of bioprocess contract testing through the 2019 acquisition of Virusure Forschung und Entwicklung, an Austrian viral safety services provider. 

Another buyout followed through two years later, this time being US-based mycoplasma testing services provider Bionique Testing Laboratories LLC. 

 

Bionova’s Repertoire

 

Bionova’s process development capabilities include manufacturing next-generation antibody drugs – a challenge in the industry. Unlike conventional antibody-based drugs, next-gen antibody drugs such as antibody-drug conjugates (ADCs) and bispecific antibodies are often more complex and have sophisticated mechanisms of action. 

Bionova’s facility is GMP-certified, and houses single-use bioreactors that can meet biopharma demand for antibody drugs. The CDMO M&A is expected to help Asahi Kasei Medical grow its bioprocess business more rapidly and reach a broader range of customers.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
M&A
Catalent Scoops Up Fellow CDMO, Metrics, for $475 Million
2022-08-11
M&A
Gilead Spends $405 Million In Cash to Acquire MiroBio
2022-08-05
Takeda Throws $1 Million at F-star to Develop Bispecific Antibody For Novel Cancer Therapies
2022-07-21
LATEST
Vaccine Protecting Against 20 Different Pneumococcal Infections Proves Effective in Trial
2022-08-12
FDA Approves Roche’s Established Antiviral For Children Aged Five Or Older
2022-08-12
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
Extreme Climate Change Is Aggravating Infectious Diseases!
2022-08-11
In Response to Expanding Monkeypox Outbreak, FDA Approves Emergency Use of JYNNEOS Vaccine
2022-08-11
Potential $1 billion Acquisition of TeneoTwo by AstraZeneca comes to Fruition
2022-08-11
Gene Repair Therapy: First Patient Dosed With New Treatment for Sickle Cell Disease
2022-08-11
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
RESI Boston
Boston
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!